OverviewSuggest Edit

NetScientific's mission is to build a transatlantic biomedical and healthcare group funding and developing technologies that offer transformative benefits to people's lives and society. NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand. NetScientific’s investment model identifies late-stage translational research projects developing cutting-edge technologies in its disease focus areas. NetScientific then builds on accredited research, the previous stages of which have already been funded by academic institutions, governments and science foundations, to take the projects to the point of commercialisation. NetScientific is an active investor providing extensive management support. This can involve the senior management team initially taking leadership roles in companies and building dedicated management teams as the companies develop and grow.
TypePublic
HQLondon, GB
Websitenetscientific.net

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2017)41(-22%)
Revenue (FY, 2017)£386 K(-25%)

Key People/Management at Netscientific

Richard Sykes

Richard Sykes

Chairman
Francois Martelet

Francois Martelet

CEO
Barry Wilson

Barry Wilson

Non-Executive Director
Stephen Smith

Stephen Smith

Non-Executive Director
Ian Postlethwaite

Ian Postlethwaite

Chief Financial Officer & Company Secretary
Show more

Netscientific Office Locations

Netscientific has an office in London
London, GB (HQ)
30 Saint Mary Axe - Swiss Re 30 St Mary Axe
Show all (1)
Report incorrect company information

Netscientific Financials and Metrics

Netscientific Revenue

Netscientific's revenue was reported to be £386 k in FY, 2017
GBP

Revenue (FY, 2017)

386.0k

Gross profit (FY, 2017)

141.0k

Gross profit margin (FY, 2017), %

36.5%

Net income (FY, 2017)

(9.4m)

EBITDA (FY, 2017)

(10.4m)

EBIT (FY, 2017)

(10.6m)

Cash (31-Dec-2017)

6.9m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

16.0k177.7k21.0k518.0k386.0k

Revenue growth, %

274%559%

Cost of goods sold

6.0k255.0k245.0k

Gross profit

15.0k263.0k141.0k
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

410.8k25.5m16.9m23.2m9.5m6.9m

Accounts Receivable

260.057.3k37.0k109.0k115.0k

Inventories

86.0k

Current Assets

632.4k25.9m17.7m23.8m11.0m8.0m
GBPFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(1.5m)(4.3m)(6.2m)(10.4m)(12.4m)(9.4m)

Cash From Operating Activities

(1.2m)(3.7m)(6.6m)(10.6m)(12.8m)(10.6m)

Cash From Financing Activities

861.5k28.9m190.0k17.2m70.0k7.5m

Net Change in Cash

(393.3k)25.1m(8.8m)6.2m(14.4m)(2.2m)
GBPY, 2017

Revenue/Employee

9.4k

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Netscientific Online and Social Media Presence

Embed Graph
Report incorrect company information

Netscientific Blogs

PDS completes merger with Edge Therapeutics

18 March 2019 NetScientific plc (“NetScientific” or the “Company”) PDS completes merger with Edge Therapeutics Further to its announcement 26 November 2018, NetScientific plc (AIM: NSCI) is pleased to announce that PDS Biotechnology Corporation, a privately-held Portfolio Company which focuses on la…

Orderly wind up of Wanda and Vortex

18 March 2019 NetScientific plc (“NetScientific” or the “Company”) Orderly wind up of Wanda and Vortex   Further to its announcement and circular to shareholders (“Circular”) on 15 February 2019, NetScientific plc (AIM: NSCI) announces that the directors of each of Vortex Biosciences (“Vortex”) and …

Share Price Movement

14 March 2019 NetScientific plc (“NetScientific” or the “Company”) Share Price Movement NetScientific plc (AIM: NSCI) notes its recent share price movement and confirms that it is not aware of any reason for such movement. Furthermore, the Company notes, that despite the increase in share price over…

Update on Upcoming General Meeting

The post Update on Upcoming General Meeting appeared first on NetScientific.

Conclusion of Strategic Review

The post Conclusion of Strategic Review appeared first on NetScientific.

Glycotest Inc. Receives $3 Million Initial Tranche from $10 Million Series A Financing

London, UK – February 14, 2019 – Further to its earlier related announcement on 22 October 2018, NetScientific plc (“NetScientific”, AIM: NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company Glycotest Inc. has received the initial $3m tranche of the $1…
Show more

Netscientific Frequently Asked Questions

  • Who are Netscientific key executives?

    Netscientific's key executives are Richard Sykes, Francois Martelet and Barry Wilson.

  • How many employees does Netscientific have?

    Netscientific has 41 employees.

  • What is Netscientific revenue?

    Latest Netscientific annual revenue is £386 k.

  • What is Netscientific revenue per employee?

    Latest Netscientific revenue per employee is £9.4 k.

  • Who are Netscientific competitors?

    Competitors of Netscientific include Bio-Reference Laboratories, Onco.com and American Vision Partners.

  • Where is Netscientific headquarters?

    Netscientific headquarters is located at 30 Saint Mary Axe - Swiss Re 30 St Mary Axe, London.

  • Where are Netscientific offices?

    Netscientific has an office in London.

  • How many offices does Netscientific have?

    Netscientific has 1 office.